Enrico Pesenti Selected Research

edotecarin (J 107088)

7/2007	Antitumor activity of edotecarin in breast carcinoma models.
5/2006	Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Enrico Pesenti Research Topics

Disease

31	Neoplasms (Cancer) 01/2020 - 01/2003
3	Melanoma (Melanoma, Malignant) 01/2016 - 07/2013
3	Colonic Neoplasms (Colon Cancer) 04/2012 - 05/2006
3	Leukemia 08/2010 - 04/2008
2	Brain Neoplasms (Brain Tumor) 04/2016 - 07/2013
2	Neoplasm Metastasis (Metastasis) 01/2016 - 07/2013
2	Colorectal Neoplasms (Colorectal Cancer) 01/2016 - 12/2014
2	Glioblastoma (Glioblastoma Multiforme) 01/2016 - 02/2011
2	Carcinogenesis 02/2015 - 05/2010
2	Hematologic Neoplasms (Hematological Malignancy) 04/2012 - 04/2010
2	Breast Neoplasms (Breast Cancer) 07/2007 - 10/2003
2	Carcinoma (Carcinomatosis) 08/2005 - 01/2004
1	Cardiotoxicity 01/2021
1	Cachexia 01/2020
1	Hypoxia (Hypoxemia) 01/2020
1	Lung Neoplasms (Lung Cancer) 01/2016
1	Genetic Translocation (Chromosomal Translocation) 12/2014
1	Lymphoma (Lymphomas) 11/2014
1	Disease Progression 07/2013
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2012
1	Aneuploidy (Aneuploid) 12/2010
1	Chromosome Aberrations (Chromosome Abnormalities) 04/2010
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 04/2010
1	Retinoblastoma (Glioblastoma, Retinal) 03/2010
1	Adenocarcinoma of Lung 03/2010
1	Blast Crisis (Blast Phase) 04/2008
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 04/2008
1	Body Weight (Weight, Body) 07/2007

Drug/Important Bio-Agent (IBA)

10	Pharmaceutical PreparationsIBA 01/2021 - 01/2003
8	Phosphotransferases (Kinase)IBA 04/2016 - 12/2007
5	Biomarkers (Surrogate Marker)IBA 02/2011 - 01/2004
3	Proteins (Proteins, Gene)FDA Link 01/2016 - 11/2013
3	Cyclin-Dependent Kinases (cdk Proteins)IBA 08/2010 - 03/2010
3	Sunitinib (Sutent)FDA Link 05/2006 - 10/2003
3	Contrast MediaIBA 08/2005 - 04/2003
2	Cytostatic AgentsIBA 01/2020 - 05/2013
2	Bevacizumab (Avastin)FDA Link 01/2020 - 05/2013
2	Angiogenesis InhibitorsIBA 01/2020 - 05/2013
2	CrizotinibIBA 04/2016 - 01/2016
2	entrectinibIBA 04/2016 - 01/2016
2	Tyrosine (L-Tyrosine)FDA Link 04/2016 - 01/2016
2	Polo-Like Kinase 1IBA 04/2012 - 05/2010
2	Irinotecan (Camptosar)FDA LinkGeneric 04/2012 - 05/2006
2	CamptothecinIBA 02/2011 - 01/2003
2	N,1,4,4- tetramethyl- 8- ((4- (4- methylpiperazin- 1- yl)phenyl)amino)- 4,5- dihydro- 1H- pyrazolo(4,3- h)quinazoline- 3- carboxamideIBA 08/2010 - 03/2010
2	N- (6,6- dimethyl- 5- ((1- methylpiperidin- 4- yl)carbonyl)- 1,4,5,6- tetrahydropyrrolo(3,4- c)pyrazol- 3- yl)- 3- methylbutanamideIBA 05/2010 - 04/2010
2	Cyclin AIBA 03/2010 - 04/2005
2	danusertibIBA 04/2008 - 12/2007
2	Docetaxel (Taxotere)FDA Link 07/2007 - 10/2003
2	edotecarin (J 107088)IBA 07/2007 - 05/2006
2	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2007 - 10/2003
2	Tyrosine Kinase InhibitorsIBA 05/2006 - 10/2003
2	Fluorouracil (Carac)FDA LinkGeneric 05/2006 - 10/2003
1	Anaplastic Lymphoma KinaseIBA 04/2016
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2016
1	alectinibIBA 01/2016
1	ceritinibIBA 01/2016
1	IsoindolesIBA 09/2015
1	Dihydrotachysterol (AT 10)IBA 02/2015
1	Mitogen-Activated Protein KinasesIBA 02/2015
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2015
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 12/2014
1	blinatumomabIBA 11/2014
1	compound 18IBA 11/2013
1	NMS-E973IBA 07/2013
1	Cytarabine (Cytosar-U)FDA LinkGeneric 04/2012
1	NMS P937IBA 04/2012
1	D-luciferinIBA 02/2011
1	Caspase 3 (Caspase-3)IBA 02/2011
1	Temozolomide (Temodar)FDA LinkGeneric 02/2011
1	LuciferasesIBA 02/2011
1	CaspasesIBA 02/2011
1	benzyloxycarbonyl- aspartyl- glutamyl- valyl- aspartyl- aminoluciferinIBA 02/2011
1	N- (2,6- diethylphenyl)- 1- methyl- 8- ((4- ((1- methylpiperidin- 4- yl)carbamoyl)- 2- (trifluoromethoxy)phenyl)amino)- 4,5- dihydro- 1H- pyrazolo(4,3- h)quinazoline- 3- carboxamideIBA 12/2010
1	Small Interfering RNA (siRNA)IBA 10/2010
1	CarcinogensIBA 08/2010
1	TropomyosinIBA 08/2010
1	Retinoblastoma ProteinIBA 08/2010
1	PHA 767491IBA 06/2008
1	Imatinib Mesylate (Gleevec)FDA Link 04/2008
1	3-aminopyrazoleIBA 12/2007
1	Aurora KinasesIBA 12/2007
1	tyrosine receptor (receptor, tyrosine)IBA 12/2007
1	SolventsIBA 07/2007
1	Topoisomerase I InhibitorsIBA 07/2007
1	PHA 680632IBA 07/2006
1	Topoisomerase InhibitorsIBA 05/2006
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 05/2006
1	Cisplatin (Platino)FDA LinkGeneric 05/2006
1	A-factor (Streptomyces)IBA 02/2004
1	Antineoplastic Agents (Antineoplastics)IBA 02/2004
1	orantinib (SU6668)IBA 01/2004
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 10/2003
1	Cytotoxins (Cytolysins)IBA 10/2003
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 10/2003

Therapy/Procedure

7	Therapeutics 01/2016 - 01/2003
4	Oral Administration 01/2016 - 05/2010
1	Aftercare (After-Treatment) 02/2011
1	Combination Drug Therapy (Combination Chemotherapy) 07/2007
1	Drug Therapy (Chemotherapy) 05/2006